Related Experiment Video
Updated: May 21, 2026
10:55
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
Management of cutaneous dermatomyositis
Christina Lam1, Ruth Ann Vleugels
1Department of Dermatology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. christina.lam@mail.mcgill.ca
Dermatologic Therapy
|June 30, 2012
Summary
Dermatomyositis (DM) management focuses on skin symptoms, even without muscle weakness. This review summarizes treatments for cutaneous DM and offers a new treatment algorithm.
Area of Science:
- Dermatology
- Rheumatology
- Immunology
Background:
- Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by muscle weakness and skin findings.
- Clinically amyopathic DM (CADM) presents with skin manifestations but no muscle weakness.
- Therapeutic responses often differ between the muscle and skin components of DM.
Purpose of the Study:
- To review the current literature on managing cutaneous dermatomyositis.
- To present an evidence-based algorithmic approach for treating skin disease in DM.
Main Methods:
- Comprehensive literature search for therapeutic agents and treatment strategies for cutaneous DM.
- Synthesis of existing data to develop a structured treatment algorithm.
Main Results:
- A wide range of treatments exist for cutaneous and extracutaneous DM manifestations.
- Limited controlled studies hinder definitive interpretation of treatment efficacy.
- An algorithmic approach to managing skin disease in DM is proposed.
Conclusions:
- Effective management of cutaneous DM requires tailored therapeutic strategies.
- The proposed algorithm aims to guide clinicians in treating skin manifestations of DM.
- Further controlled studies are needed to optimize treatment protocols for DM.
Related Concept Videos
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
01:23Skin Diseases and Disorders
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...